ArticleAdvanced healthcare materials2026
New Insights into Atonic Postpartum Hemorrhage: Animal Model Construction Based on Placental Nanodelivery Systems.
Article in Advanced healthcare materials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
As the leading cause of maternal mortality, the pathogenesis of postpartum hemorrhage (PPH), with 60%-70% cases of uterine atony, remains unclear due to a fundamental lack of animal models for studying. Our study develops a novel placenta-targeted nanodelivery system, termed HN@DC NPs, which is formulated with DSPC (1,2-distearoyl-sn-glycero-3-phosphocholine), DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy (polyethylene glycol)-2000]), and DSPE-PEG-CSA (DSPE-PEG2000-chondroitine sulfate A). This system is designed to co-deliver key inflammatory mediators-nucleotide-binding oligomerization domain, leucine-rich repeat, and pyrin domain-containing 3 (NLRP3) agonist nigericin and high mobility group box-1 protein (HMGB1), which are identified from pregnant women with atonic PPH to establish a pathophysiologically relevant animal model. The HN@DC NPs achieve precise enrichment in placental trophoblasts and effective diffusion into decidua with good short-term biocompatibility. The pregnant rats model constructed by HN@DC NPs shows prolonged labor duration and weakened uterine smooth muscle contractility with the activation of inflammatory markers in the placental decidua. The new insight into a reproducible construction strategy of the atonic PPH animal model in this study promotes the mechanism research and clinical therapeutic development of atonic PPH.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.